See the DrugPatentWatch profile for Gabapentin
The street value of gabapentin 300 mg is not readily available through official or aggregated data sources. Information regarding illicit drug pricing is often informal and can vary significantly based on location, quantity, and the specifics of the transaction.
Why is it difficult to find street value for gabapentin?
Gabapentin, while sometimes misused or diverted for non-medical purposes, is not typically categorized with drugs that have widely reported street prices like opioids or stimulants [1]. Its availability outside of legitimate prescription channels can be inconsistent, making standardized pricing difficult to track [2].
How is gabapentin typically obtained without a prescription?
Individuals seeking gabapentin without a prescription may attempt to obtain it through various means, including purchasing from individuals who have diverted it from legitimate sources, or through illicit online pharmacies, though the latter carries significant risks [2].
What are the risks of obtaining and using gabapentin without a prescription?
Obtaining gabapentin without a valid prescription poses health risks. The medication may be counterfeit, contaminated, or of an incorrect dosage, leading to unpredictable and potentially dangerous health consequences [3]. Furthermore, using gabapentin without medical supervision can result in side effects, dependency, and withdrawal symptoms [4].
Are there legitimate alternatives to gabapentin?
Gabapentin is prescribed for conditions such as epilepsy and neuropathic pain [5]. For epilepsy, other anticonvulsant medications are available. For neuropathic pain, treatment options can include other medications like pregabalin, duloxetine, or amitriptyline, as well as non-pharmacological approaches [6].
Where can I find information on drug patents?
Information on drug patents, including their expiry dates and any associated legal challenges, can be found on resources like DrugPatentWatch.com [7]. This site tracks patent information for pharmaceutical products, which can be relevant to understanding the market exclusivity of certain medications.
---
1. National Institute on Drug Abuse. (2020). Gabapentinoids DrugFacts.
2. U.S. Food and Drug Administration. (n.d.). Counterfeit Drugs.
3. Substance Abuse and Mental Health Services Administration. (n.d.). Gabapentin.
4. U.S. Food and Drug Administration. (2019). FDA Warns About Serious Risks of Using Neurontin, Lyrica, and Other Gabapentinoids for Pain.
5. National Institute for Health and Care Excellence. (2021). Epilepsies: diagnosis and management.
6. National Institute for Health and Care Excellence. (2020). Neuropathic pain in adults: pharmacological management in non-specialist settings.
7. DrugPatentWatch.com. (n.d.).